Loading…
The merger aims to advance Nebokitug in an AI-powered Phase 2 trial.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) and Scipher Medicine have announced a merger agreement to combine their resources and expertise. The primary goal of this merger is to advance the development of Nebokitug, a therapeutic candidate, through an AI-powered Phase 2 trial targeting Rheumatoid Arthritis.
The collaboration leverages Scipher Medicine's AI-driven platform to optimize patient selection and trial design, aiming to enhance the efficacy and efficiency of the clinical trial process. The merger is expected to pool the strengths of both companies, potentially accelerating the development timeline and improving outcomes for patients with Rheumatoid Arthritis.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.